RNS60 as Adjunctive Therapy in Acute Large Vessel Occlusion Stroke: Insights from the RESCUE Trial

Highlight

• RESCUE was a randomized, double-blind, placebo-controlled phase 2 trial evaluating RNS60 as an adjunct therapy in large vessel occlusion (LVO) acute ischemic stroke patients undergoing endovascular thrombectomy.
• RNS60 was safe and well tolerated with no increase in serious adverse events or mortality compared with placebo.
• The higher dose of RNS60 (1.0 mL/kg/h) reduced infarct volume growth by 47% at 48 hours after thrombectomy versus placebo.
• Although other functional outcomes did not reach statistical significance, trends suggested improved neurological recovery and functional independence favoring RNS60 1.0 mL/kg/h at 90 days.

Study Background and Disease Burden